Amphibian-derived peptide RL-RF10 ameliorates paraquat-induced pulmonary fibrosis injury
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Pulmonary fibrosis is the result of dysfunctional repair after lung tissue injury, characterized by fibroblast proliferation and massive extracellular matrix aggregation. Once fibrotic lesions develop, effective treatment is difficult, with few drugs currently available. Here, we identified a short cyclic decapeptide RL-RF10 derived from frog skin secretions as a potential novel lead molecule for the amelioration of pulmonary fibrosis. In vivo experiments indicated that RL-RF10 treatment ameliorated lung histopathological damage and fibrogenesis after paraquat (PQ) induction in a concentration-dependent manner. On day 7, bronchoalveolar lavage fluid assays performed on mice showed that RL-RF10 exerted anti-inflammatory effects by decreasing the expression of inflammation-related factors, including transforming growth factor-β1 (TGF-β1) and tumor necrosis factor-α, in lung tissue. In addition, RL-RF10 down-regulated the levels of collagen I, collagen III, and vimentin, while increasing the expression of E-cadherin to inhibit epithelial-mesenchymal transition. Further research demonstrated that the SMAD2/3 signaling pathway, which is strongly linked to TGF-β1, played a critical function in enhancing the pulmonary fibrosis relief achieved by RL-RF10. Both in vivo and in vitro assays showed that RL-RF10 treatment led to a significant reduction in the phosphorylation levels of SMAD2 and SMAD3 following PQ induction. Overall, we investigated the protective effects and underlying mechanisms of the RL-RF10 peptide against pulmonary fibrosis and demonstrated its potential as a novel therapeutic drug candidate for the treatment of pulmonary fibrotic diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:171 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 171(2024) vom: 16. Feb., Seite 116184 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Huiling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-34-5 |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 08.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2024.116184 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367348241 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367348241 | ||
| 003 | DE-627 | ||
| 005 | 20240208232041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240121s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2024.116184 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1284.xml |
| 035 | |a (DE-627)NLM367348241 | ||
| 035 | |a (NLM)38244328 | ||
| 035 | |a (PII)S0753-3322(24)00065-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Huiling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Amphibian-derived peptide RL-RF10 ameliorates paraquat-induced pulmonary fibrosis injury |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Pulmonary fibrosis is the result of dysfunctional repair after lung tissue injury, characterized by fibroblast proliferation and massive extracellular matrix aggregation. Once fibrotic lesions develop, effective treatment is difficult, with few drugs currently available. Here, we identified a short cyclic decapeptide RL-RF10 derived from frog skin secretions as a potential novel lead molecule for the amelioration of pulmonary fibrosis. In vivo experiments indicated that RL-RF10 treatment ameliorated lung histopathological damage and fibrogenesis after paraquat (PQ) induction in a concentration-dependent manner. On day 7, bronchoalveolar lavage fluid assays performed on mice showed that RL-RF10 exerted anti-inflammatory effects by decreasing the expression of inflammation-related factors, including transforming growth factor-β1 (TGF-β1) and tumor necrosis factor-α, in lung tissue. In addition, RL-RF10 down-regulated the levels of collagen I, collagen III, and vimentin, while increasing the expression of E-cadherin to inhibit epithelial-mesenchymal transition. Further research demonstrated that the SMAD2/3 signaling pathway, which is strongly linked to TGF-β1, played a critical function in enhancing the pulmonary fibrosis relief achieved by RL-RF10. Both in vivo and in vitro assays showed that RL-RF10 treatment led to a significant reduction in the phosphorylation levels of SMAD2 and SMAD3 following PQ induction. Overall, we investigated the protective effects and underlying mechanisms of the RL-RF10 peptide against pulmonary fibrosis and demonstrated its potential as a novel therapeutic drug candidate for the treatment of pulmonary fibrotic diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epithelial-mesenchymal-transition (EMT) | |
| 650 | 4 | |a Paraquat (PQ) | |
| 650 | 4 | |a Pulmonary fibrosis | |
| 650 | 4 | |a RL-RF10 | |
| 650 | 7 | |a Paraquat |2 NLM | |
| 650 | 7 | |a PLG39H7695 |2 NLM | |
| 650 | 7 | |a Transforming Growth Factor beta1 |2 NLM | |
| 650 | 7 | |a Collagen |2 NLM | |
| 650 | 7 | |a 9007-34-5 |2 NLM | |
| 700 | 1 | |a Wu, Yutong |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Ziqian |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Yuanqi |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Qiuye |e verfasserin |4 aut | |
| 700 | 1 | |a Ru, Zeqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Zijian |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yuansheng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yubing |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Saige |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Kun |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Chengan |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Zhenhua |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xinwang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 171(2024) vom: 16. Feb., Seite 116184 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:171 |g year:2024 |g day:16 |g month:02 |g pages:116184 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2024.116184 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 171 |j 2024 |b 16 |c 02 |h 116184 | ||